Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products Administration (NMPA) has approved the Phase Ib clinical study for its drug candidate THDBH120, a glucagon-like peptide-1/gastrin inhibitor (GLP-1/GIP) dual-targeted receptor agonist. The drug is intended for the treatment of overweight or obese adults.
THDBH120 is developed to address type 2 diabetes (T2D) and has shown promising results in preclinical trials for weight loss. The drug candidate is designed to integrate the effects of two incretins, GLP-1 and GIP, into a single molecule, enhancing metabolic stability and potentially improving blood glucose control. The Phase II study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of THDBH120 in patients with T2D.- Flcube.com
